Defective Reverse Cholesterol Transport Polygenic Risk Score

Your body has a built-in cleanup crew that pulls cholesterol out of artery walls and ships it back to the liver for disposal. When this cleanup system is sluggish, cholesterol builds up where it shouldn't, even when standard lipid panels look reasonable. This score reads your DNA to estimate how well your inherited biology supports that cleanup process.

A polygenic risk score is not a lab value that rises or falls. It is a fixed number calculated from the small DNA letters you were born with. Knowing it early gives you a head start on prevention because you can act on inherited risk decades before it shows up on a cholesterol panel or a heart scan.

What This Score Actually Measures

A PRS (polygenic risk score) is a computed number based on many germline DNA variants, each with a tiny effect. It is not a protein, hormone, or metabolite, and no organ produces it. This particular score weights variants in genes that govern reverse cholesterol transport, the pathway that moves cholesterol from peripheral tissues, especially artery walls, back to the liver for excretion.

Reverse cholesterol transport is largely driven by HDL particles and the proteins they carry. Variants associated with low HDL cholesterol cluster in pathways tied to this transport process, HDL particle remodeling, cholesterol storage inside cells, and the way immune cells called macrophages turn into foam cells inside artery walls. A higher score means you inherited more of the variants that make this cleanup pathway less efficient.

Why It Matters for Heart Disease

When reverse cholesterol transport is impaired, cholesterol accumulates inside artery walls and contributes to plaque buildup. The clearest human evidence linking this genetic risk pattern to outcomes comes from a Korean study that identified DNA variants tied to low HDL and the reverse cholesterol transport pathway.

In that study, people carrying more of these risk variants were more likely to have low HDL cholesterol. Within the group that had low HDL, the rate of heart attack and stroke was higher than in people with normal HDL. That ties an inherited weakness in this pathway directly to the two outcomes most people care about.

How Genetic Risk Stacks With Other Lipid Risks

Reverse cholesterol transport is one piece of the cardiovascular risk picture. The bigger driver in most people is LDL cholesterol, and PRSs for high LDL track strongly with disease. People in the top tenth of a LDL polygenic score were about three times more likely to have premature coronary heart disease than people with low scores. Among people with familial hypercholesterolemia (an inherited condition that causes lifelong high LDL), those in the highest third of a 192-variant coronary artery disease PRS had a higher rate of cardiovascular events compared with the lowest third.

The point is that genetic risk scores for different lipid pathways add information on top of each other. A score for defective reverse cholesterol transport is most useful when read alongside scores or measurements for LDL particles, Lp(a) (a sticky inherited cholesterol-carrying particle), and standard lipids. No single one tells the full story.

What an Elevated Score Means in Practice

A higher score means you inherited more variants linked to weaker reverse cholesterol transport, often reflected in lower HDL and a tendency toward atherosclerosis. A lower score means fewer risk variants and, on average, lower lifetime genetic exposure. This is a research-grade measurement. There is no internationally agreed cutoff that defines a diagnosis of polygenic dyslipidemia, and the predicted risk from a polygenic score alone does not match the magnitude of risk seen in single-gene disorders like familial hypercholesterolemia.

Treat the result as one piece of inherited information that informs how aggressively to manage cholesterol and other modifiable risk factors over your lifetime. It is not a diagnosis on its own.

Reconciling Genetics With a Normal Lipid Panel

It is possible to have an elevated genetic score and currently normal cholesterol numbers. Genetic predisposition and current lab values are not the same thing. The score reflects lifelong genetic exposure to a pathway that may struggle under stress, not your cholesterol concentration today. Polygenic and single-gene contributors to cholesterol problems are not mutually exclusive. They stack.

Why a Single Reading Is Enough, and Why Repeat Testing Is Not

Unlike cholesterol, fasting glucose, or inflammation markers, a polygenic risk score does not change. It is calculated from inherited DNA, and the underlying variants do not shift with diet, exercise, medication, illness, or age. You order the test once. The result follows you for life.

What does need serial tracking are the downstream lipid and inflammation markers that this genetic background influences: HDL, LDL particle count or ApoB (a count of cholesterol-carrying particles), Lp(a), and hs-CRP (a sensitive inflammation marker). A baseline lipid panel now, a follow-up in three to six months if you change anything, then at least annually after that, lets you see whether your interventions are actually moving the modifiable numbers your genetics make harder to manage.

What to Do With an Elevated Score

If your score is in the upper range, the next move is to map your current cardiovascular biology against your inherited risk. Order or review an advanced lipid workup including ApoB, Lp(a), and standard cholesterol. Add hs-CRP for inflammation. If those numbers are out of pattern, a lipidologist or preventive cardiologist can help decide whether early lipid-lowering therapy makes sense, even if you would not otherwise meet standard criteria. Genetic risk often justifies more aggressive treatment thresholds because it reflects lifelong exposure.

When a high polygenic score for coronary disease was disclosed to people in clinical studies, more started statin therapy, LDL cholesterol levels dropped, and over a decade-long follow-up cardiovascular events were lower than in people not told their score. The score itself does not cause the benefit. The action it triggers does.

When Results Can Be Misleading

Polygenic risk scores carry their own interpretive pitfalls that have nothing to do with how the sample was collected. The main ones to know:

• Ancestry mismatch: most lipid PRSs were built in people of European ancestry, and they predict less accurately when applied to people of African, East Asian, South Asian, or Indigenous backgrounds. If your ancestry differs from the population the score was trained on, the number is less precise.
• Percentile confusion: a result like 'top 10 percent' describes where you sit relative to a reference population, not a 10 percent probability of disease. Patients and even some clinicians frequently misread the percentile as an absolute risk.
• False reassurance from a low score: a low score lowers your inherited risk on average, but it does not erase risk from smoking, high LDL, diabetes, high blood pressure, or other lifestyle factors. The genetics are one input among many.
• Normal current lipids are not a clean bill of health: a high genetic score reflects lifelong genetic exposure. Cholesterol values that look fine today can still drift, and the pathway weakness shows up over decades.

Who Should Know Their Score

The strongest case for testing is someone with a family history of early heart attack or stroke, low HDL that runs in the family, or a personal lipid pattern that does not match how they live. It is also useful for anyone making long-term decisions about whether to start lipid-lowering medication, because inherited risk argues for acting sooner rather than waiting for damage to accumulate.